Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
Go back to Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 212.26 -0.24 (0.11%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $212.50 | 52 Week High | $333.65 | |||
| Open | $210.50 | 52 Week Low | $223.02 | |||
| Day High | $213.48 | P/E | 27.18 | |||
| Day Low | $209.00 | EPS | $7.81 | |||
| Volume | 200,157 | |||||
| Sagebrush Gold Ltd. (NASDAQ: SAGE) | Delayed: 8.68 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.68 | 52 Week High | $62.64 | |||
| Open | $8.68 | 52 Week Low | $26.28 | |||
| Day High | $8.68 | P/E | N/A | |||
| Day Low | $8.68 | EPS | $-0.94 | |||
| Volume | 107,095 | |||||

